In the phase III trial, which was stopped early, Entresto proved superior to the ACE inhibitor enalapril, reducing the risk of cardiovascular death or heart failure hospitalisation by 20 per cent ...

The company said the sales growth was driven primarily by its blockbuster heart-failure drug Entresto and its arthritis ...

A U.S. appeals court has lifted a temporary halt it imposed on the launch of a generic version of Novartis's (NYSE:NVS) top-selling cardiac drug Entresto. The U.S. Court of Appeals for the ...

There are currently no generic versions of Entresto available in the US ... including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays ...

Nicole Sassu Ph.D., William Scofield Jr. In a Jan. 10 precedential ruling by the United States Court of Appeals for the Federal Circuit, the validity of the U.S. patent covering Novartis’s ...

Entresto includes the active ingredients valsartan ... s claim construction and the case proceeded to a three-day bench trial. At trial, the court was unpersuaded by MSN’s obviousness arguments ...

In Novartis Pharms. Corp. v. Torrent Pharma Inc., the U. S. Court of Appeals for the Federal Circuit shut down efforts to ...

Novartis stock rose Friday after the drugmaker beat fourth-quarter expectations, largely on the back of its heart failure drug Entresto.

Swiss pharmaceutical giant Novartis (NVS) on Friday reported forecast-beating quarterly sales as its clutch of heart failure to breast cancer ...

Novartis AG (NYSE:NVS) shares are trading higher in the premarket session on Friday. The Swiss pharma giant reported fourth-quarter adjusted earnings per share of $1.98, beating the street view of $1.